Transplant Immunosuppression for the Surgeon — Name the Rejection, Spend the Drugs Frugally

The transplanted organ wants three verdicts before the drugs — what rejection looks like under the microscope, which barriers stand before the operation, and how little drug holds the graft afterwards — because classification now reaches chronic active cellular disease and molecular antibody rejection, donor antibody can condemn a graft its biopsy calls innocent, and every drug spared is toxicity avoided. Name rejection by Banff, cross ABO and crossmatch barriers with plasma exchange and globulin, induce by risk, maintain on low-dose tacrolimus, withdraw steroids and calcineurin in the selected, prevent CMV by serostatus, climb the PTLD ladder from reduction to rituximab, and vaccinate by the calendar — with every number taken from the papers named beside it.^{[1][11][4][14][16]}

A 40-year-old woman with a positive crossmatch and her only donor ABO-incompatible; a 55-year-old man a year after kidney transplantation with creeping creatinine on full-dose tacrolimus; and a seronegative recipient of a seropositive kidney facing 200 days of prophylaxis. One needs barriers crossed before the knife, one needs drugs spent down without losing the graft, and one needs virus prevention that spares the marrow. The examiner will watch you quote Banff with DSA logic, defend desensitisation with hyperacute numbers, choose induction by long-term advantage, price steroid and calcineurin withdrawal with rejection arithmetic, compare CMV strategies, and climb PTLD from reduction to rituximab — with every number taken from the papers named beside it.^{[11][6][14][16]}

Rejection has a language and the surgeon must speak it: fibrotic inflammation with tubulitis now defines chronic active cellular rejection with proven graft-survival cost, while antibody rejection reaches beyond histology and C4d toward molecular assays and donor-antibody alternatives — with borderline infiltrates and microvascular inflammation without markers as the argued edges.^[1][2] The strategic arc fits one sentence: classify by Banff, respect the antibody even when the biopsy is silent, cross barriers with exchange and globulin, induce by risk, hold with low-dose tacrolimus, minimise steroids and calcineurin where trials allow, guard marrow against CMV, and treat PTLD by reduction first.^{[1][12][4][6][14][16]}

Name the rejection before treating it

Fibrosis with inflammation is no longer dismissed as scar: confirmed by two groups as a graft-survival cost, moderate fibrotic inflammation with moderate or severe tubulitis now diagnoses chronic active cellular rejection — often the footprint of earlier under-immunosuppression.^[1] Antibody rejection has outgrown its stains: molecular classifiers beat histology with C4d and donor antibodies, and both C4d and validated molecular assays now stand as alternatives or complements to donor antibodies in diagnosis.^[1] The 2019 refinements police the borders — chronic active cellular disease with borderline or acute infiltrates, the inflammation threshold for borderline itself, and microvascular injury without C4d or detectable antibody where molecular testing earns its place.^[2] The antibody deserves fear even naked: it can mean rejection without C4d or histology, it can precede the stains, and dysfunction left untreated on a negative biopsy ends badly — so a positive donor antibody with a failing graft is treated, not filed.^[12] Chronic failure has one prevention: the leading killer of kidney grafts is chronic allograft nephropathy — fibrotic, sclerotic, hyalinised decline — and its only optimal strategy is minimising both immune and non-immune injury from the start.^[25]

Cross the barriers, then respect them

Blood group and sensitisation were walls until exchange breached them: preconditioning with alternate-day plasma exchange and low-dose immune globulin until antibody and isoagglutinin titres fall lets ABO-incompatible, crossmatch-positive grafts proceed — with no hyperacute rejection, both barriers crossed at once, and the single antibody rejection reversed by re-treating with exchange, globulin and anti-CD20.^[11] The series behind it concurs: twelve desensitised recipients with no hyperacute events, seven rejections split four antibody and three cellular, and donor antibody caught preceding or masquerading behind negative histology.^[12] Induction choice then follows the antibody: with weak preformed donor antibody, depletional induction holds antibody rejection low even without desensitisation; with strong antibody it pairs with aggressive desensitisation; and against basiliximab it lowers de-novo antibody in the moderately sensitised — though randomised proof is still awaited.^[13]

Induce by risk, maintain on tacrolimus

Eight randomised trials find induction a short-term tie: no difference in one-year rejection, graft or patient survival, or infection between basiliximab and anti-thymocyte globulin — except the long tail, where basiliximab carries a quarter of the neoplasm odds.^[8] Maintenance belongs to low-dose tacrolimus: across 1,645 randomised recipients it led filtration at 65.4 ml per minute, halved biopsy rejection to 12.3% against 24 to 37% elsewhere, and topped graft survival at 94.2% — the advantageous triple with daclizumab, mycophenolate and steroids.^[4] Toxicities stay distinct even at low doses, so tailor by patient: tacrolimus brings diabetes, low white cells and diarrhoea; sirolimus brings lipids, wounds, lymphoceles and anaemia; standard ciclosporin brings the most infection, notably CMV.^[5]

Spend steroids and calcineurin frugally

Steroid sparing trades rejection for vessels: thirty trials show no mortality or graft-loss cost yet a quarter more rejection, concentrated without mycophenolate or everolimus cover — while blood pressure drugs, cholesterol, post-transplant diabetes, cataracts and cardiovascular events all fall.^[6] The 34-study pooling sharpens it: rejection up by half with survival untouched and creatinine slightly worse, against hypertension, diabetes and cholesterol all cut — justified in low-risk recipients on modern protocols.^[7] Calcineurin follows the same frugality: withdrawal at six months on a depletional-steroid-free backbone improves function and chronic histology at one and two years without moving survival or rejection.^[24] The mTOR route preserves kidneys at a price: with tacrolimus minimisation it holds function with survival and rejection tied, but two-thirds face lipid rises, over a third diabetes, a fifth wound trouble — and the head-to-head everolimus trial missed non-inferiority by 1.4% with more cellular rejection yet less graft loss.^[9][10] The liver mirrors it: everolimus with calcineurin minimisation gains 10.2 ml per minute of filtration at a year with rejection, loss and death tied — at the cost of more infections overall.^[23]

Prevent CMV by serostatus, climb PTLD by ladder

Two hundred days of valganciclovir is the high-risk standard — and letermovir now matches it: noninferior on disease through a year at 10.4 against 11.8%, with white-cell toxicity at 26 against 64% and fewer stopped courses — the marrow-sparing alternative.^[14] Prophylaxis versus pre-emption splits honestly: 140 randomised recipients showed no significant acute-rejection difference, though subclinical rejection at three months favoured prophylaxis and bloodstream virus favoured pre-emption with less drug and less neutropenia — while both regimens held disease to 4%.^[15] Lymphoma climbs a fixed ladder: cut immunosuppression first, then rituximab with or without chemotherapy — with depletional induction implicated in aggressive monomorphic disease and donor source mattering little.^[16] The liver variant strikes children hardest, is driven by immunosuppression load and EBV status, and answers to the same reduction-first, rituximab-led mainstay.^[17] Belatacept stays inside its fence: approved for EBV-seropositive prophylaxis, with PTLD at 0.70 against 0.48% over five years — statistically tied but numerically higher with cerebral cases on both sides — and rituximab alone or with chemotherapy for EBV-positive disease where chemotherapy itself may not suit.^[18][19]

Price diabetes, vaccinate by calendar, watch tolerance

Tacrolimus diabetes has a number: exposure above 15 ng/mL in the early months carries nearly double the hazard — so levels are titrated as toxicity, and steroid avoidance trims diabetes most where ciclosporin, not tacrolimus, is the backbone.^[20][6] Vaccinate before the graft when possible — both killed and live vaccines pre-transplant — then by the post-transplant clock: killed vaccines from 3 months, influenza from one month, and live vaccines only for the selected, with ordinary contacts free to take their routine live vaccines.^[3] The liver uniquely forgives: withdrawal succeeds completely in selected stable long-term recipients, over a third of children proved operationally tolerant at 37.5% with no death, loss or refractory rejection — and every tolerance protocol shares cell therapy with the organ, the workshop's common thread.^[21][22][26]

The cohorts behind the numbers run Haas Banff 2017, Loupy Banff 2019, Danziger-Isakov AST vaccination, Ekberg Symphony with 1,645 recipients, Ekberg toxicity profiling, Pascual 30-trial Cochrane review with 5,949 participants, Knight 34-study pooling with 5,637 patients, Wang eight-trial induction meta with 1,153 patients, Peddi mTOR review, Qazi everolimus non-inferiority, Warren barrier-crossing first, Kayler twelve-patient rejection characterisation, Pascual depletional-antibody review, Limaye 601-patient letermovir trial, Reischig 140-patient prophylaxis trial, Ergisi kidney PTLD review, Janeela liver PTLD review, Cherikh belatacept registry analysis, Chaganti Delphi consensus, Destere tacrolimus-diabetes cohort, Thomson tolerance review, Feng 88-child withdrawal trial, Lin liver everolimus meta, Stevens factorial withdrawal trial, Pittappilly chronic nephropathy review, and Issa tolerance workshop — randomised where randomisable, pooled where small, meeting-reported where classification lives.^{[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]}

Barriers, marrow and the calendar close the traps: the sensitised recipient is desensitised then watched for antibody-first rejection, since the biopsy can lie; the stable graft on full tacrolimus is minimised where trials allow, since chronic scarring is the true killer; the seronegative recipient of a seropositive kidney gets 200 days of cover with marrow in mind; the EBV-naive never gets belatacept; vaccines precede the graft with the post-transplant clock honoured after; and the long-stable liver child may yet prove tolerant — the only organ that forgives withdrawal.^{[11][25][14][18][3][22]}

References26ShowHide

1. [1]Haas M, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant, 2018.PMID 29243394
2. [2]Loupy A, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant, 2020.PMID 32463180
3. [3]Danziger-Isakov L, et al. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant, 2019.PMID 31002409
4. [4]Ekberg H, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med, 2007.PMID 18094377
5. [5]Ekberg H, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant, 2010.PMID 20106825
6. [6]Pascual J, et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev, 2009.PMID 19160257
7. [7]Knight SR, et al. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation, 2010.PMID 20061913
8. [8]Wang K, et al. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol, 2018.PMID 28986715
9. [9]Peddi VR, et al. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando), 2013.PMID 23932018
10. [10]Qazi Y, et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. Am J Transplant, 2017.PMID 27775865
11. [11]Warren DS, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant, 2004.PMID 15023148
12. [12]Kayler LK, et al. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation. Transpl Int, 2006.PMID 16441362
13. [13]Pascual J, et al. Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation--A review. Transplant Rev (Orlando), 2016.PMID 26951711
14. [14]Limaye AP, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA, 2023.PMID 37279999
15. [15]Reischig T, et al. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients. J Am Soc Nephrol, 2023.PMID 36749127
16. [16]Ergisi M, et al. Post-transplant lymphoproliferative disorders following kidney transplantation: A literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type. Transplant Rev (Orlando), 2024.PMID 38430887
17. [17]Janeela AM, et al. Post-transplantation Lymphoproliferative Disorder (PTLD): In the Liver Transplant Recipient. J Clin Exp Hepatol, 2024.PMID 38076446
18. [18]Cherikh WS, et al. Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database. PLoS One, 2025.PMID 39792912
19. [19]Chaganti S, et al. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study. Adv Ther, 2023.PMID 36681739
20. [20]Destere A, et al. Longitudinal Exposure to Tacrolimus and New-Onset Diabetes Mellitus in Renal Transplant Patients. Ther Drug Monit, 2023.PMID 36624577
21. [21]Thomson AW, et al. Understanding, predicting and achieving liver transplant tolerance: from bench to bedside. Nat Rev Gastroenterol Hepatol, 2020.PMID 32759983
22. [22]Feng S, et al. Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management. Hepatology, 2021.PMID 32786149
23. [23]Lin M, et al. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. Clin Transplant, 2017.PMID 27862340
24. [24]Stevens RB, et al. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology. PLoS One, 2015.PMID 26465152
25. [25]Pittappilly M, et al. Chronic Allograft Nephropathy-A Narrative Review of Its Pathogenesis, Diagnosis, and Evolving Management Strategies. Biomedicines, 2025.PMID 40299546
26. [26]Issa F, et al. The Fourth International Workshop on Clinical Transplant Tolerance. Am J Transplant, 2021.PMID 32529725